Detalhe da pesquisa
1.
HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI.
Future Oncol;
20(15): 969-980, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38095056
2.
HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC.
Future Oncol;
19(19): 1319-1329, 2023 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37212796
3.
Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers.
Br J Cancer;
126(6): 889-898, 2022 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34963703
4.
YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.
Proc Natl Acad Sci U S A;
115(26): E6030-E6038, 2018 06 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29875142
5.
Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers.
Cancer;
125(24): 4380-4387, 2019 12 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31469421
6.
Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers.
Acta Oncol;
58(11): 1634-1639, 2019 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31347936
7.
Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.
Cancer;
124(1): 105-109, 2018 Jan 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28940498
8.
Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
Cancer;
121(12): 2078-82, 2015 Jun 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25781862
9.
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.
JCO Precis Oncol;
8: e2300454, 2024 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38591867
10.
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers.
J Natl Compr Canc Netw;
11(2): 161-9, 2013 Feb 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23411383
11.
The Promise and Limitations of Neoadjuvant Immune-Checkpoint Blockade in Resectable Non-Small Cell Lung Cancer.
Cancer Discov;
13(11): 2306-2309, 2023 11 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37909090
12.
Intracranial Outcomes of De Novo Brain Metastases Treated With Osimertinib Alone in Patients With Newly Diagnosed EGFR-Mutant NSCLC.
JTO Clin Res Rep;
4(12): 100607, 2023 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38124791
13.
Clinicopathologic outcomes of preoperative targeted therapy in patients with clinical stage I to III non-small cell lung cancer.
J Thorac Cardiovasc Surg;
165(5): 1682-1693.e3, 2023 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36528430
14.
Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas.
Clin Cancer Res;
29(8): 1423-1428, 2023 04 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36729110
15.
Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasis.
Nat Commun;
14(1): 4980, 2023 08 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37591896
16.
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON.
Cancer Discov;
13(1): 98-113, 2023 01 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36264123
17.
Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers.
J Thorac Oncol;
18(4): 463-475, 2023 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36494075
18.
Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations.
Clin Cancer Res;
29(11): 2123-2130, 2023 06 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36913537
19.
Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers.
Sci Transl Med;
15(707): eadf7006, 2023 08 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37531417
20.
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
J Clin Oncol;
41(35): 5363-5375, 2023 Dec 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37689979